Raymond James Financial Services Advisors, Inc. Aldeyra Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$4.73 - $7.98 $63,855 - $107,730	-13,500 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$7.14 - $9.85 $7,140 - $9,850	1,000 Added 8.0%	13,500 $122,000
Q4 2018 Feb 11, 2019	BUY	$7.26 - $13.29 $90,750 - $166,125	12,500 New	12,500 $104,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

Perceptive Advisors LLC New York, NY

9.28M
Shares

$44.5 Million
1.31% of portfolio
Knoll Capital Management, LLC Miami, FL

5.48M
Shares

$26.3 Million
14.56% of portfolio
Vanguard Group Inc Valley Forge, PA

3.76M
Shares

$18.1 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.62M
Shares

$17.4 Million
0.0% of portfolio
Kennedy Capital Management, Inc. St Louis, MO

1.88M
Shares

$9.03 Million
0.24% of portfolio

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account